Literature DB >> 10493496

Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer.

M Miyaki1, T Iijima, J Kimura, M Yasuno, T Mori, Y Hayashi, M Koike, N Shitara, T Iwama, T Kuroki.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is characterized by defective DNA mismatch repair, which results in genetic instability of tumors; however, only a few target genes have been recognized. Our previous study detected a low frequency of APC gene mutation (21%) in colorectal tumors from HNPCC patients, in contrast to a high frequency of APC gene alteration (>70%) in non-HNPCC tumors. Because both beta-catenin and ACP gene mutations have recently been shown to activate the same signaling pathway, we analyzed beta-catenin mutation in HNPCC tumors. A notable frequency of beta-catenin gene mutation (43%, 12 of 28) was found to occur in HNPCC colorectal tumors. Beta-catenin mutations were not detected in tumors with APC mutations. All beta-catenin mutations detected in HNPCC tumors existed within the regulatory domain of beta-catenin. Immunohistochemical staining of tumors with this mutation showed accumulation of beta-catenin protein in nuclei. These and previous data from our laboratory suggest that activation of the beta-catenin-Tcf signaling pathway, through either beta-catenin or APC mutation, contributes to HNPCC colorectal carcinogenesis in approximately 65% of cases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493496

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells.

Authors:  Lillian Ouko; Thomas R Ziegler; Li H Gu; Leonard M Eisenberg; Vincent W Yang
Journal:  J Biol Chem       Date:  2004-04-14       Impact factor: 5.157

Review 3.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

4.  The activation of beta-catenin by Wnt signaling mediates the effects of histone deacetylase inhibitors.

Authors:  Michael Bordonaro; Darina L Lazarova; Alan C Sartorelli
Journal:  Exp Cell Res       Date:  2007-02-22       Impact factor: 3.905

Review 5.  Molecular alterations and biomarkers in colorectal cancer.

Authors:  William M Grady; Colin C Pritchard
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

6.  Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.

Authors:  Charly Liddell; Laure Droy-Dupré; Sylvie Métairie; Fabrice Airaud; Christelle Volteau; Stéphane Bezieau; Christian L Laboisse; Jean-François Mosnier
Journal:  Mod Pathol       Date:  2017-04-21       Impact factor: 7.842

7.  Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells.

Authors:  Débora Sinner; Jennifer J Kordich; Jason R Spence; Robert Opoka; Scott Rankin; Suh-Chin J Lin; Diva Jonatan; Aaron M Zorn; James M Wells
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

Review 8.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

9.  Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.

Authors:  Silvio K Scheel; Marc Porzner; Sabine Pfeiffer; Steffen Ormanns; Thomas Kirchner; Andreas Jung
Journal:  BMC Cancer       Date:  2010-08-09       Impact factor: 4.430

Review 10.  Modular Cre/lox system and genetic therapeutics for colorectal cancer.

Authors:  Michael Bordonaro
Journal:  J Biomed Biotechnol       Date:  2009-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.